Phathom Pharmaceuticals, Inc. PHAT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $58.3M+1.2% | $57.58M+16.3% | $49.5M+25.3% | $39.5M+38.5% | $28.52M-3.9% | ||
| $12M+56.9% | $7.65M+23.6% | $6.19M+22.9% | $5.04M+35.3% | $3.72M-2.4% | ||
| $46.31M-7.3% | $49.94M+15.3% | $43.31M+25.7% | $34.47M+39.0% | $24.8M-4.1% | ||
| 79.4%-7.3pp | 86.7%-0.8pp | 87.5%+0.2pp | 87.2%+0.3pp | 86.9%-0.2pp | ||
| $7.77M+3.7% | $7.49M+6.6% | $7.03M-22.6% | $9.08M-1.2% | $9.18M+7.0% | ||
| $54.01M+11.7% | $48.37M-6.2% | $51.56M-39.6% | $85.31M-9.7% | $94.47M+23.2% | ||
| $61.78M+10.6% | $55.86M-4.6% | $58.59M-37.9% | $94.39M-8.9% | $103.66M+21.6% | ||
| $61.78M+10.6% | $55.86M-4.6% | $58.59M-37.9% | $94.39M-8.9% | $103.66M+21.6% | ||
| -$15.48M-161% | -$5.93M+61.2% | -$15.27M+74.5% | -$59.92M+24.0% | -$78.86M-32.7% | ||
| -26.5%-16.3pp | -10.3%+20.6pp | -30.8%+121pp | -151.7%+125pp | -276.5%-76.2pp | ||
| $15.8M-3.8% | $16.42M+1.9% | $16.11M-8.0% | $17.52M-3.1% | $18.07M-2.8% | ||
| $1.74M+44.2% | $1.2M-14.8% | $1.41M-20.9% | $1.79M-32.3% | $2.64M-24.8% | ||
| -$14.89M+2.2% | -$15.22M-3.5% | -$14.7M+7.5% | -$15.89M-2.8% | -$15.45M-2.8% | ||
| -$30.37M-43.6% | -$21.15M+29.4% | -$29.97M+60.5% | -$75.81M+19.6% | -$94.32M-26.7% | ||
| -52.1%-15.4pp | -36.7%+23.8pp | -60.5%+131pp | -191.9%+139pp | -330.7%-79.7pp | ||
| -$0.37-37.0% | -$0.27+34.1% | -$0.41+61.0% | -$1.05+19.8% | -$1.31-31.0% | ||
| -$0.37-37.0% | -$0.27+34.1% | -$0.41+61.0% | -$1.05+19.8% | -$1.31-31.0% | ||
| 82.1M+12.5% | 72.9M-0.7% | 73.4M+1.3% | 72.5M+0.7% | 72M+13.9% | ||
| 82.1M+12.5% | 72.9M-0.7% | 73.4M+1.3% | 72.5M+0.7% | 72M+13.9% | ||
| -$831K-16,520% | -$5K+28.6% | -$7K+95.5% | -$155K-605% | -$22K— | ||
| -$15.48M-161% | -$5.93M+61.2% | -$15.27M+74.5% | -$59.92M+24.0% | -$78.86M-32.7% | ||
| -$15.37M-165% | -$5.8M+61.6% | -$15.12M+74.7% | -$59.75M+24.1% | -$78.69M-32.9% | ||
| -$15.37M-165% | -$5.8M+61.6% | -$15.12M+74.7% | -$59.75M+24.1% | -$78.69M-32.9% | ||
| -26.4%-16.3pp | -10.1%+20.5pp | -30.5%+121pp | -151.3%+125pp | -275.9%-76.3pp | ||
| -$15.48M-161% | -$5.93M+61.2% | -$15.27M+74.5% | -$59.92M+24.0% | -$78.86M-32.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) generated $204.9M in revenue over the trailing twelve months, up 150.3% year over year.
- Is Phathom Pharmaceuticals, Inc. profitable?
- Phathom Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months, a -76.8% net margin.
- What are Phathom Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 84.9% and operating margin is -47.1%, with a -76.8% net margin.
- What is Phathom Pharmaceuticals, Inc.'s earnings per share?
- Phathom Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.10.
- Where does Phathom Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
